What is the price of domestically produced Ivosidenib in 2023?

Ivosidenib (Ivosidenib) is a targeted therapy drug that belongs to the drug class of IDH1 inhibitors. Its main application area is the treatment of patients with acute myeloid leukemia (AML) who express IDH1 gene mutations, providing an innovative treatment option for this specific subtype of AML.

Avosidenib is already on the market in China, but it has not yet been included in medical insurance. The price of Avosidenib on the domestic market is very high, reaching tens of thousands of yuan. For specific prices, please consult the local hospital pharmacy. The price of the American original drug of Ivonib abroad is as high as hundreds of thousands. Currently, there are generic drugs of Ivonib on the market, mainly Laos generic drugs, which cost about 10,000 yuan, which is much cheaper in comparison, and the ingredients of the original drug and the generic drug are basically the same.

AML is a blood system disease caused by abnormal proliferation of leukemia cells in the bone marrow, and mutations in the IDH1 gene are one of the specific genetic abnormalities. This mutation leads to the abnormal activation of IDH1 enzyme, which participates in cell metabolism and promotes the development of AML.

The mechanism of action of ivonib mainly involves the specific inhibition ofIDH1enzyme. Through this inhibitory effect, ivosidenib can interfere with metabolic processes within leukemia cells, slowing or preventing the growth and proliferation of these cells. Compared with traditional chemotherapy methods, ivonib has a more specific effect and reduces the adverse effects on normal cells.

Patients usually need to be tested for IDH1 gene mutations before using ivonib to ensure that their genotype meets the indications of the drug. During treatment, doctors will design a personalized medication plan based on the patient's specific conditions and conduct regular monitoring to evaluate efficacy and safety.